Sofia Grigoriadou
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 45 publications
Oral deucrictibant for prophylaxis of hereditary angioedema attacks (CHAPTER-1): primary analysis of a randomised, double-blind, placebo-controlled, phase 2 trial.
Journal: The Lancet. Haematology
Published: September 08, 2025
Decreased IL-17-producing TH cells as a diagnostic marker for STAT signaling-related primary immunodeficiencies.
Journal: The journal of allergy and clinical immunology. Global
Published: April 11, 2025
Effects of cladribine on intrathecal and peripheral B and plasma cells.
Journal: Clinical and experimental immunology
Published: September 04, 2024
Investigating pulmonary and non-infectious complications in common variable immunodeficiency disorders: a UK national multi-centre study.
Journal: Frontiers in immunology
Published: June 19, 2024
Serum and Tissue Biomarkers Associated With Composite of Relevant Endpoints for Sjögren Syndrome (CRESS) and Sjögren Tool for Assessing Response (STAR) to B Cell-Targeted Therapy in the Trial of Anti-B Cell Therapy in Patients With Primary Sjögren Syndrome (TRACTISS).
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: July 07, 2023
Behçet's patients' response to COVID-19 vaccination.
Journal: Clinical immunology (Orlando, Fla.)
Published: May 22, 2023
Chronic or recurrent Campylobacter enteritis in primary immunodeficiency: A UK national case-series and review of the literature.
Journal: The journal of allergy and clinical immunology. In practice
Published: October 16, 2022
The efficacy and safety of systemic corticosteroids as first line treatment for granulomatous lymphocytic interstitial lung disease.
Journal: The Journal of allergy and clinical immunology
Published: October 06, 2022
Age-associated B cells predict impaired humoral immunity after COVID-19 vaccination in patients receiving immune checkpoint blockade.
Journal: Nature communications
Published: June 29, 2022
Correction to: A Multi-center, Open-Label, Single-Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency.
Journal: Journal of clinical immunology
Published: February 17, 2022
Subcutaneous Gammanorm® by pump or rapid push infusion: Impact of the device on quality of life in adult patients with primary immunodeficiencies.
Journal: Clinical immunology (Orlando, Fla.)
Published: November 14, 2021
Last Updated: 09/26/2026